Domain Therapeutics S.A. has added EUR2.1 million ($2.9 million) for the development of its pipeline targeting conditions including diabetes, Parkinson’s disease and schizophrenia.
Domain Therapeutics S.A. has added EUR2.1 million ($2.9 million) for the development of its pipeline targeting conditions including diabetes, Parkinson’s disease and schizophrenia.
